RESUMEN
INTRODUCTION: Smoking tobacco results in the death of more than 8 million people every year. Our study aims to explore a new approach for smoking cessation by analyzing body composition differences between smokers and non-smokers, focusing on potential variations in biological and chronological ages. METHODS: A cross-sectional study was conducted in 2019 at the Special Hospital for Medical Rehabilitation in Croatia. It included 164 subjects, 81 smokers and 83 non-smokers, aged 40-65 years. This study was part of a two-year investigation on locomotor parameter changes as early COPD predictors. Measurements encompassed body parameters, spirometry tests, and body composition. Spirometry was done using the Flowscreen Pro device, and the FEV1/FVC ratio determined lung function. The GAIA 359 PLUS device assessed body composition and estimated biological age. Exclusion criteria applied to specific medical conditions and recent surgeries. RESULTS: Smokers had a slightly higher percentage of fat tissue than non-smokers (median=27%, IQR: 24-31) compared to non-smokers (median=25%, IQR: 22-28, p<0.001). The difference in the Gaia estimated age and the actual age of the subjects was significantly higher in the group of smokers (median=2, IQR: 0-3) compared to non-smokers (median=0 IQR: -2-2, p=0.003), but they did not differ in muscle tissue, weight or the proportion of trunk adipose tissue. CONCLUSIONS: Our study revealed that smokers exhibit higher fat tissue percentages and a higher estimated biological age relative to non-smokers. These findings underscore the established health hazards of smoking and the imperative for smoking cessation in mitigating these adverse effects.
RESUMEN
Background: GIGER MD device applies a biofeedback method through stimulated coordinated rhythmic and dynamic movements of the trunk and extremities in an anti-gravity position, thus helping to regain lost motor functions. Methods: In this article, the performance of the GIGER MD device was evaluated in 36 children with neurogenic bladder measuring gait speed, voiding bladder capacity, deviation from the age-adjusted bladder capacity (measured using the Koff scale), and urinary incontinence. Results: Children using the GIGER MD device had an increase in voiding bladder capacity (33.79%, median volume increase of 50 ml) with a subsequent median decrease in median age-adjusted bladder capacity by 45.50% (median deviation before was 36% vs. 16% after treatment). The number of urinary incontinence episodes also reduced by 55.57% (7-3 episodes per day), and the 20-meter motor gait speed increased by 14.26% (from 23 to 19 s). Conclusion: Children who follow the GIGER MD therapy regularly for a period of 6 months show that CNS functional damage can be significantly improved.
